Lyubov G. Dezhenkova

Dr. Lyubov G. Dezhenkova


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
ATAnna Tevyashova
Anna Tevyashova
SESvetlana Efimova
Svetlana Efimova
AAAlexander I. Alexandrov
Alexander I. Alexandrov
OOOlga Omelchuk
Olga Omelchuk
EGEslam Ghazy
Eslam Ghazy
ASAndrey E. Shchekotikhin
Andrey E. Shchekotikhin
Polyene antifungal amphotericin B (AmB) has been used for over 60 years, and remains a valuable clinical treatment for systemic mycoses, due to its broad antifungal activity and low rate of emerging resistance. There is no consensus on how exactly it kills fungal cells but it is certain that AmB and the closely-related nystatin (Nys) can form pores in membranes and have a higher affinity towards ergosterol than cholesterol. Notably, the high nephro- and hemolytic toxicity of polyenes and their low solubility in water have led to efforts to improve their properties. We present the synthesis of new amphotericin and nystatin amides and a comparative study of the effects of identical modifications of AmB and Nys on the relationship between their structure and properties. Generally, increases in the activity/toxicity ratio were in good agreement with increasing ratios of selective permeabilization of ergosterol- vs. cholesterol-containing membranes. We also show that the introduced modifications had an effect on the sensitivity of mutant yeast strains with alterations in ergosterol biosynthesis to the studied polyenes, suggesting a varying affinity towards intermediate ergosterol precursors. Three new water-soluble nystatin derivatives showed a prominent improvement in safety and were selected as promising candidates for drug development.

23 November 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SKStepan Konstantinovich Krymov
Stepan Konstantinovich Krymov
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
LDLyubov G. Dezhenkova
Lyubov G. Dezhenkova
DSDiana I. Salnikova
Diana I. Salnikova
SSSvetlana Solovieva
Svetlana Solovieva
ASAndrey E. Shchekotikhin
Andrey E. Shchekotikhin
The overexpression and activity of carbonic anhydrase (CA, EC 4.2.1.1) isoforms CA IX and CA XII promote the accumulation of exceeding protons and acidosis in the extracellular tumor environment. Sulfonamides are effective inhibitors of most families of CAs. In this study, using scaffold-hopping, indoline-5-sulfonamide analogs 4a–u of the CA IX-selective inhibitor 3 were designed and synthesized to evaluate their biological properties. 1-Acylated indoline-5-sulfonamides demonstrated inhibitory activity against tumor-associated CA IX and XII with KI values up to 132.8 nM and 41.3 nM. Compound 4f, as one of the most potent inhibitors of CA IX and XII, exhibits hypoxic selectivity, suppressing the growth of MCF7 cells at 12.9 µM, and causes partial inhibition of hypoxia-induced CA IX expression in A431 skin cancer cells. 4e and 4f reverse chemoresistance to doxorubicin of K562/4 with overexpression of P-gp.
1

1 November 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
ASAndrey E. Shchekotikhin
Andrey E. Shchekotikhin
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
LDLyubov G. Dezhenkova
Lyubov G. Dezhenkova
EBEvgeny E. Bykov
Evgeny E. Bykov
SSSvetlana E. Solovieva
Svetlana E. Solovieva
ASAndrey E. Shchekotikhin
Andrey E. Shchekotikhin

23 January 2024 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Maxim E. ZhidkovMaxim E. Zhidkov
Maxim E. Zhidkov
MSMaria Sidorova
Maria Sidorova
PSPolina Alekseevna Smirnova
Polina Alekseevna Smirnova
OTOleg Aleksandrovich Tryapkin
Oleg Aleksandrovich Tryapkin
AKAndrey V. Kachanov
Andrey V. Kachanov
APAlexander popov
Alexander popov
Based on the results of our own preliminary studies, the derivative of the marine alkaloid fascaplysin containing a phenyl substituent at C-9 was selected to evaluate the therapeutic potential in vivo and in vitro. It was shown that this compound has outstandingly high antimicrobial activity against Gram-positive bacteria, including antibiotic-resistant strains in vitro. The presence of a substituent at C-9 of the framework is of fundamental importance, since its replacement to neighboring positions leads to a sharp decrease in the selectivity of the antibacterial action, which indicates the presence of a specific therapeutic target in bacterial cells. On a model of the acute bacterial sepsis in mice, it was shown that the lead compound was more effective than the reference antibiotic vancomycin seven out of nine times. However, ED50 value for 9-phenylfascaplysin (7) was similar for the unsubstituted fascaplysin (1) in vivo, despite the former being significantly more active than the latter in vitro. Similarly, assessments of the anticancer activity of compound 7 against various variants of Ehrlich carcinoma in mice demonstrated its substantial efficacy. To conduct a structure–activity relationship (SAR) analysis and searches of new candidate compounds, we synthesized a series of analogs of 9-phenylfascaplysin with varying aryl substituents. However, these modifications led to the reduced aqueous solubility of fascaplysin derivatives or caused a loss of their antibacterial activity. As a result, further research is required to explore new avenues for enhancing its pharmacokinetic characteristics, the modification of the heterocyclic framework, and optimizing of treatment regimens to harness the remarkable antimicrobial potential of fascaplysin for practical usage.

1 May 2008 in Russian Journal of Bioorganic Chemistry
Verified
Journal Article
Closed access
PDF file
LDLyubov G. Dezhenkova
Lyubov G. Dezhenkova
ATA. N. Tevyashova
A. N. Tevyashova
EOE. N. Olsuf’EVa
E. N. Olsuf’EVa
ITI. D. Treshchalin
I. D. Treshchalin
ASAlexander Shtil
Alexander Shtil
MPM. N. Preobrazhenskaya
M. N. Preobrazhenskaya
The relationship between the structure of new semisynthetic derivatives of doxorubicin, daunorubicin, and carminomycin and their ability to inhibit topoisomerase I were studied. The new derivatives...

25 December 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SKStepan Konstantinovich Krymov
Stepan Konstantinovich Krymov
DSDiana I. Salnikova
Diana I. Salnikova
LDLyubov G. Dezhenkova
Lyubov G. Dezhenkova
Fedor BogdanovFedor Bogdanov
Fedor Bogdanov
AKAlexander A. Korlyukov
Alexander A. Korlyukov
ASAndrey E. Shchekotikhin
Andrey E. Shchekotikhin
Breast and other estrogen receptor α-positive cancers tend to develop resistance to existing drugs. Chalcone derivatives possess anticancer activity based on their ability to form covalent bonds with targets acting as Michael acceptors. This study aimed to evaluate the anticancer properties of a series of chalcones (7a–l) with a sulfonamide group attached to the vinyl ketone moiety. Chalconesulfonamides showed a potent antiproliferative effect at low micromolar concentrations against several cancer cell lines, including ERα-positive 4-hydroxytamoxifen-resistant MCF7/HT2. Immunoblotting of samples treated with the lead compound 7e revealed its potent antiestrogenic activity (ERα/GREB1 axis) and induction of PARP cleavage (an apoptosis marker) in breast cancer cells. The obtained compounds represent a promising basis for further development of targeted drugs blocking hormone pathways in cancer cells.
1